In 2025 alone, the agency issued over 50 oncology approvals([1]) , but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated ...
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 5, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The FDA isn't just approving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results